Skip to content

Study · Non-randomized trial · 2012

6 results

Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients.

Zarogoulidis K, Eleftheriadou E, Kontakiotis T, Gerasimou G, Zarogoulidis P, Sapardanis I, Galaktidou G, Sakkas L, Gotzamani-Psarrakou A, Karatzas N

Lung cancer (Amsterdam, Netherlands)22 Oct 2011Cited by 25 (Europe PMC)

PMID22018594 (opens in a new tab)DOI10.1016/j.lungcan.2011.09.014 (opens in a new tab)PepBankPUB-22018594
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In SCLC patients, Group B receiving lanreotide had better survival than Group A (comparison with Groups A and C, p=0.029).

    In plain wordsIn SCLC patients, survival was better with Group B lanreotide than with Group A, which received chemotherapy then lanreotide maintenance.

    Peptide
    Lanreotide
    Outcome
    IncreaseSurvival versus Group A
    Study

    n: not reported in source

    Comparator
    Group A: chemotherapy only during chemotherapy cycles, then lanreotide maintenance
    Outcome group
    Mortality · Cancer
    Studied dose
    30 mg after each chemotherapy cycle · subcutaneousAs given in this study (human).

    Measurements

    P value
    0.029 P
    Group B versus Groups A and C, survival

    Source sentences

    Summary
    Group B had a survival benefit in comparison to Groups A and C (p=0.029).
    6 context sentences
    Summary · context
    130 previously untreated SCLC patients--54 with limited disease (LD) and positive somatostatin receptors were included in the study.
    Summary · context
    All patients were treated with paclitaxel 190 mg/m2+carboplatin AUC=5.5 for up to 6 cycles.
    Summary · context
    47/130 patients (Group A, control group) received only CHT.
    Summary · context
    Forty eight hours after each CHT 43/130 patients (Group B) were also administered 30 mg somatuline® (lanreotide) by a single subcutaneous (s.c.) injection to stimulate somatostatin receptors (SSTRS) for 2 weeks.
    Summary · context
    40/130 patients (Group C) received 60 mg somatuline® autogel to stimulate SSTRS for 4 weeks.
    Summary · context
    Patients in Groups A and B after the completion of the CHT continued maintenance therapy with somatuline.
  2. 02HumanNon-randomized trialEfficacy outcome

    In SCLC patients, Group B receiving lanreotide had better survival than Group C (comparison with Groups A and C, p=0.029).

    In plain wordsIn SCLC patients, survival was better with Group B lanreotide than with Group C lanreotide autogel.

    Peptide
    Lanreotide
    Outcome
    IncreaseSurvival versus Group C
    Study

    n: not reported in source

    Comparator
    Group C: 60 mg lanreotide autogel with chemotherapy
    Outcome group
    Mortality · Cancer
    Studied dose
    30 mg after each chemotherapy cycle · subcutaneousAs given in this study (human).

    Measurements

    P value
    0.029 P
    Group B versus Groups A and C, survival

    Source sentences

    Summary
    Group B had a survival benefit in comparison to Groups A and C (p=0.029).
    6 context sentences
    Summary · context
    130 previously untreated SCLC patients--54 with limited disease (LD) and positive somatostatin receptors were included in the study.
    Summary · context
    All patients were treated with paclitaxel 190 mg/m2+carboplatin AUC=5.5 for up to 6 cycles.
    Summary · context
    47/130 patients (Group A, control group) received only CHT.
    Summary · context
    Forty eight hours after each CHT 43/130 patients (Group B) were also administered 30 mg somatuline® (lanreotide) by a single subcutaneous (s.c.) injection to stimulate somatostatin receptors (SSTRS) for 2 weeks.
    Summary · context
    40/130 patients (Group C) received 60 mg somatuline® autogel to stimulate SSTRS for 4 weeks.
    Summary · context
    Patients in Groups A and B after the completion of the CHT continued maintenance therapy with somatuline.
  3. 03HumanNon-randomized trialEfficacy outcome

    In limited-disease SCLC, Group B receiving lanreotide had better survival than Group A (comparison with Groups A and C, p=0.012).

    In plain wordsIn limited-disease SCLC, survival was better with Group B lanreotide than with Group A, which received chemotherapy then lanreotide maintenance.

    Peptide
    Lanreotide
    Outcome
    IncreaseLimited-disease survival versus Group A
    Study

    n: not reported in source

    Comparator
    Group A: chemotherapy only during chemotherapy cycles, then lanreotide maintenance
    Outcome group
    Mortality · Cancer
    Studied dose
    30 mg after each chemotherapy cycle · subcutaneousAs given in this study (human).

    Measurements

    P value
    0.012 P
    limited disease, Group B versus Groups A and C, Breslow test

    Source sentences

    Summary
    LD patients of Group B had a significant benefit compared to Groups A and C (p=0.012, Breslow test).
    6 context sentences
    Summary · context
    130 previously untreated SCLC patients--54 with limited disease (LD) and positive somatostatin receptors were included in the study.
    Summary · context
    All patients were treated with paclitaxel 190 mg/m2+carboplatin AUC=5.5 for up to 6 cycles.
    Summary · context
    47/130 patients (Group A, control group) received only CHT.
    Summary · context
    Forty eight hours after each CHT 43/130 patients (Group B) were also administered 30 mg somatuline® (lanreotide) by a single subcutaneous (s.c.) injection to stimulate somatostatin receptors (SSTRS) for 2 weeks.
    Summary · context
    40/130 patients (Group C) received 60 mg somatuline® autogel to stimulate SSTRS for 4 weeks.
    Summary · context
    Patients in Groups A and B after the completion of the CHT continued maintenance therapy with somatuline.
  4. 04HumanNon-randomized trialEfficacy outcome

    In limited-disease SCLC, Group B receiving lanreotide had better survival than Group C (comparison with Groups A and C, p=0.012).

    In plain wordsIn limited-disease SCLC, survival was better with Group B lanreotide than with Group C lanreotide autogel.

    Peptide
    Lanreotide
    Outcome
    IncreaseLimited-disease survival versus Group C
    Study

    n: not reported in source

    Comparator
    Group C: 60 mg lanreotide autogel with chemotherapy
    Outcome group
    Mortality · Cancer
    Studied dose
    30 mg after each chemotherapy cycle · subcutaneousAs given in this study (human).

    Measurements

    P value
    0.012 P
    limited disease, Group B versus Groups A and C, Breslow test

    Source sentences

    Summary
    LD patients of Group B had a significant benefit compared to Groups A and C (p=0.012, Breslow test).
    6 context sentences
    Summary · context
    130 previously untreated SCLC patients--54 with limited disease (LD) and positive somatostatin receptors were included in the study.
    Summary · context
    All patients were treated with paclitaxel 190 mg/m2+carboplatin AUC=5.5 for up to 6 cycles.
    Summary · context
    47/130 patients (Group A, control group) received only CHT.
    Summary · context
    Forty eight hours after each CHT 43/130 patients (Group B) were also administered 30 mg somatuline® (lanreotide) by a single subcutaneous (s.c.) injection to stimulate somatostatin receptors (SSTRS) for 2 weeks.
    Summary · context
    40/130 patients (Group C) received 60 mg somatuline® autogel to stimulate SSTRS for 4 weeks.
    Summary · context
    Patients in Groups A and B after the completion of the CHT continued maintenance therapy with somatuline.
  5. 05HumanNon-randomized trialEfficacy outcome

    In limited-disease SCLC, Group B receiving lanreotide had longer TTP than Group A (comparison with Groups A and C, p=0.02).

    In plain wordsIn limited-disease SCLC, progression took longer with Group B lanreotide than with Group A, which received chemotherapy then lanreotide maintenance.

    Peptide
    Lanreotide
    Outcome
    IncreaseLimited-disease time to progression versus Group A
    Study

    n: not reported in source

    Comparator
    Group A: chemotherapy only during chemotherapy cycles, then lanreotide maintenance
    Outcome group
    Tumor growth · Cancer
    Studied dose
    30 mg after each chemotherapy cycle · subcutaneousAs given in this study (human).

    Measurements

    P value
    0.02 P
    limited disease, time to progression, Group B versus Groups A and C

    Source sentences

    Summary
    In LD Group B had a significant longer TTP (p=0.02) in comparison to Groups A and C.
    6 context sentences
    Summary · context
    130 previously untreated SCLC patients--54 with limited disease (LD) and positive somatostatin receptors were included in the study.
    Summary · context
    All patients were treated with paclitaxel 190 mg/m2+carboplatin AUC=5.5 for up to 6 cycles.
    Summary · context
    47/130 patients (Group A, control group) received only CHT.
    Summary · context
    Forty eight hours after each CHT 43/130 patients (Group B) were also administered 30 mg somatuline® (lanreotide) by a single subcutaneous (s.c.) injection to stimulate somatostatin receptors (SSTRS) for 2 weeks.
    Summary · context
    40/130 patients (Group C) received 60 mg somatuline® autogel to stimulate SSTRS for 4 weeks.
    Summary · context
    Patients in Groups A and B after the completion of the CHT continued maintenance therapy with somatuline.
  6. 06HumanNon-randomized trialEfficacy outcome

    In limited-disease SCLC, Group B receiving lanreotide had longer TTP than Group C (comparison with Groups A and C, p=0.02).

    In plain wordsIn limited-disease SCLC, progression took longer with Group B lanreotide than with Group C lanreotide autogel.

    Peptide
    Lanreotide
    Outcome
    IncreaseLimited-disease time to progression versus Group C
    Study

    n: not reported in source

    Comparator
    Group C: 60 mg lanreotide autogel with chemotherapy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    30 mg after each chemotherapy cycle · subcutaneousAs given in this study (human).

    Measurements

    P value
    0.02 P
    limited disease, time to progression, Group B versus Groups A and C

    Source sentences

    Summary
    In LD Group B had a significant longer TTP (p=0.02) in comparison to Groups A and C.
    6 context sentences
    Summary · context
    130 previously untreated SCLC patients--54 with limited disease (LD) and positive somatostatin receptors were included in the study.
    Summary · context
    All patients were treated with paclitaxel 190 mg/m2+carboplatin AUC=5.5 for up to 6 cycles.
    Summary · context
    47/130 patients (Group A, control group) received only CHT.
    Summary · context
    Forty eight hours after each CHT 43/130 patients (Group B) were also administered 30 mg somatuline® (lanreotide) by a single subcutaneous (s.c.) injection to stimulate somatostatin receptors (SSTRS) for 2 weeks.
    Summary · context
    40/130 patients (Group C) received 60 mg somatuline® autogel to stimulate SSTRS for 4 weeks.
    Summary · context
    Patients in Groups A and B after the completion of the CHT continued maintenance therapy with somatuline.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.